HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)KuraoncologyNCT04809233
Expanded Access to Tipifarnib
A study testing Tipifarnib in people with HRAS Mutations or Peripheral T Cell Lymphoma (PTCL), run by Kura Oncology, Inc..
Trial summary
Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL). To request access, use Responsible Party contact information provided in this record. Expanded access for tipifarnib is only available in the United States. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
- What is being tested?
- Tipifarnib
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Start not givento not given
- Phase
- Expanded access
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Who may be able to join
- Diagnosed with HRAS mutations or peripheral T Cell Lymphoma (PTCL).
- Adult, ages 18+.
- Have exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition.
- Is ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations.
- Meets any other pertinent medical criteria for access to the investigational drug, as established by the Kura Oncology
Who cannot join
None listed.
Trial locations and contacts
No sites are listed yet.
About this study
Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL).
To request access, use Responsible Party contact information provided in this record.
Expanded access for tipifarnib is only available in the United States.
- Being tested
- Tipifarnib
- Medical subject headings
- Lymphoma, T-Cell, Peripheral
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TipifarnibDrug
Tipifarnib
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Mar 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Expanded access
Sponsor and investigators
- Lead sponsor
- Kura Oncology, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04809233
- Sponsor's protocol ID
- Expanded Access to Tipifarnib
- Acronym
- Kuraoncology
- Status last verified
- Jun 2026
- First submitted
- 18 Mar 2021
- Last updated
- 29 Jun 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Expanded Access to Tipifarnib
- ClinicalTrials.gov ID
- NCT04809233
- Acronym / sponsor ID
- Kuraoncology / Expanded Access to Tipifarnib
- Study type
- Expanded access
- Recruitment status
- Available
- Lead sponsor
- Kura Oncology, Inc.Industry (pharma, biotech, devices)
- First posted
- 22 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL).
To request access, use Responsible Party contact information provided in this record.
Expanded access for tipifarnib is only available in the United States.
Study design
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Diagnosed with HRAS mutations or peripheral T Cell Lymphoma (PTCL).
- Adult, ages 18+.
- Have exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition.
- Is ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations.
- Meets any other pertinent medical criteria for access to the investigational drug, as established by the Kura Oncology
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TipifarnibTipifarnib | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jun 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
A study testing Tipifarnib in people with HRAS Mutations or Peripheral T Cell Lymphoma (PTCL), run by Kura Oncology, Inc..
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 29 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Kura Medical Information (844-KURAONC (844-587-2662), medinfo@kuraoncology.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2026.